1.
Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands
2.
Respiratory morbidity, healthcare resource use, and cost burden associated with extremely preterm birth in The Netherlands
Clinical implications and cost-effectiveness analysis of rivaroxaban in patients with coronary artery disease or peripheral arterial disease in the Netherlands